Tango Therapeutics Stock Investor Sentiment
| TNGX Stock | USD 3.10 0.16 5.44% |
Slightly above 57% of Tango Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Tango Therapeutics suggests that many traders are alarmed. Tango Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tango Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tango |
Tango Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Tango Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Tango Therapeutics that are available to investors today. That information is available publicly through Tango media outlets and privately through word of mouth or via Tango internal channels. However, regardless of the origin, that massive amount of Tango data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Tango Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Tango Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Tango Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Tango Therapeutics alpha.
Tango Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Insider Trading | 10/10/2024 |
2 | Disposition of 625000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 7.05 subject to Rule 16b-3 | 10/21/2024 |
3 | Disposition of 250000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.78 subject to Rule 16b-3 | 10/22/2024 |
4 | Disposition of 633000 shares by Boxer Capital Management, Llc of Tango Therapeutics at 6.87 subject to Rule 16b-3 | 10/25/2024 |
5 | Acquisition by Davis Aaron I. of 65000 shares of Tango Therapeutics at 10.93 subject to Rule 16b-3 | 11/01/2024 |
6 | Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program | 11/06/2024 |
7 | Disposition of 1143124 shares by Ecor1 Capital, Llc of Tango Therapeutics at 2.9171 subject to Rule 16b-3 | 11/07/2024 |
8 | Tango Therapeutics, Inc. Insider Boxer Capital Management, Llc Sells 3,080,000 Shares of Stock | 11/08/2024 |
9 | Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.62 subject to Rule 16b-3 | 11/14/2024 |
10 | Acquisition by Rothenberg Mace of 10000 shares of Tango Therapeutics at 3.78 subject to Rule 16b-3 | 11/18/2024 |
11 | Tango Therapeutics, Inc. Director Purchases 37,800.00 in Stock | 11/19/2024 |
12 | Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference | 11/27/2024 |
13 | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 12/03/2024 |
14 | Tango Therapeutics, Inc. Receives Consensus Recommendation of Buy from Analysts - MarketBeat | 12/09/2024 |
Additional Tools for Tango Stock Analysis
When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.